"An investment in knowledge pays the best interest."

TSX Penny Stocks

We are a website devoted to hunting for undervalued and undiscovered TSX listed Penny Stocks.

Buying penny stocks or investing profitably in the stock market, in general, is not easy. Our penny stock investments invariably come from hard work and researching reliable sources. TSX Penny Stocks provides news and important company information so you can ultimately decide which stocks are worth your consideration.

The website offers write-ups of penny stocks and company news. Visitors can sign up to TSX Penny Stocks.ca for a free email newsletter to receive more penny stock articles, and company spotlights. Join us, it’s free.

 

Latest News

Newsletter Sign-up

Don't Miss Another TSX Penny Stock

Subscribe

ZOMEDICA ANNOUNCES RESEARCH AGREEMENT WITH CELSEE DIAGNOSTICS FOR CANCER LIQUID BIOPSY

 

Zomedica Pharmaceuticals Corp. (ZOM.V) has entered into a research collaboration agreement with Celsee Diagnostics Inc., an innovator of human health products in the emerging field of liquid biopsy. The research project defined in the agreement aims to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics.

A liquid biopsy is a blood test with the potential to detect the presence of circulating tumour cells in the blood. Circulating tumour cells, commonly referred to as CTCs, are cells that have shed from a primary tumour into neighbouring blood vessels and are transported throughout the body's circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy.

Concurrent to this research project, Zomedica filed a provisional application for patent with the United States Patent and Trademark Office (USPTO) in support of its research and development efforts specific to canine cancer diagnostics. The provisional patent is based on Zomedica's identification of novel canine biomarkers for diagnosing canine cancers.

"Canine cancer is one of the most commonly diagnosed diseases in the veterinary clinic," stated Zomedica's chief medical officer Dr. William MacArthur, MS, DVM. "It is difficult, expensive and often times impractical for veterinarians to diagnose some cancers in a non-invasive manner. As such, veterinarians are frequently required to make treatment recommendations to pet owners based on incomplete patient information."

This translational opportunity aligns with Zomedica's veterinary-focused mission to provide needs-driven solutions to the real-world problems of veterinary practice. Zomedica anticipates translational opportunities such as this to be an important component of its diversified product strategy.

About Zomedica

With U.S. operations based in Ann Arbor, Mich., Zomedica is a veterinary pharmaceutical and health care solutions company targeting products for companion animals (canine, feline and equine) through a groundbreaking approach that focuses on the unmet needs of clinical veterinarians. Zomedica is building a diversified portfolio of products comprising the discovery, development and commercialization of innovative drugs alongside novel drug delivery systems, devices and diagnostics. With multiple clinical veterinarians in executive management, it is Zomedica's mission to give veterinarians the opportunity to lower costs, increase productivity and grow revenue while better serving the animals in their care.